Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants

• मुख्य लेखकों: Suzanne M. Garland (लेखक), Manjula Anagani (लेखक), Neerja Bhatla (लेखक), Sukanta Chatterjee (लेखक), Sanjay Lalwani (लेखक), Cecil Ross (लेखक), Thomas Group (लेखक), Jianxin Lin (लेखक), Alain Luxembourg (लेखक), Anuj Walia (लेखक), Yingmei Tu (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) and 9-valent HPV (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccines have demonstrated efficacy, immunogenicity, and safety in international clinical trials. We report outcomes from three completed clinical trials in India: a single-arm study (V...